Is MLLCF or SCHD a better dividend investment in 2026?

MLLCF currently yields 40.32% with a 5% 5-year dividend growth rate. SCHD yields 3.46% with 13.05% growth. The better choice depends on your goal: MLLCF offers higher current income.

What is the dividend yield difference between MLLCF and SCHD?

MLLCF has a forward dividend yield of 40.32% ($2.00/share annually). SCHD yields 3.46% ($1.06/share annually). The yield gap is 36.86 percentage points.

Home › Compare › MLLCF vs SCHD

MLLCF vs SCHD: Dividend Comparison 2026

MLLCF yields 40.32% · SCHD yields 3.46%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MLLCF wins by $207.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MLLCF

● Live price

40.32%

Share price

$4.96

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$236.0K

Annual income

$40,141.97

Full MLLCF calculator →

SCHD

Schwab U.S. Dividend Equity ETF

● Live price

3.46%

Share price

$30.48

Annual div

$1.06

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.0K

Annual income

$425.95

Full SCHD calculator →

Portfolio growth — MLLCF vs SCHD

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MLLCF	SCHD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MLLCF + SCHD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MLLCF pays

SCHD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF

Annual income on $10K today (after 15% tax)

$3,427.42/yr

After 10yr DRIP, annual income (after tax)

$34,120.67/yr

SCHD

Annual income on $10K today (after 15% tax)

$294.40/yr

After 10yr DRIP, annual income (after tax)

$362.06/yr

At 15% tax rate, MLLCF beats the other by $33,758.62/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + SCHD for your $10,000?

MLLCF: 50%SCHD: 50%

100% SCHD50/50100% MLLCF

Portfolio after 10yr

$132.5K

Annual income

$20,283.95/yr

Blended yield

15.31%

📊

Analyst Conviction Gap

Where Wall Street is split right now

MLLCF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

-1.2

Piotroski

1/9

SCHD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys

SCHD buys

No recent congressional trades found for MLLCF or SCHD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMLLCFSCHD

Forward yield	40.32% ✓	3.46%
Annual dividend / share	$2.00 ✓	$1.06
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$236.0K ✓	$29.0K
Annual income after 10y	$40,141.97 ✓	$425.95
Total dividends collected	$178.0K ✓	$3.9K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MLLCF vs SCHD ($10,000, DRIP)

Year	MLLCF Portfolio	MLLCF Income/yr	SCHD Portfolio	SCHD Income/yr	Gap
1← crossover	$14,732	$4,032.26	$11,226	$346.36	+$3.5K → MLLCF
2	$21,315	$5,551.80	$12,572	$357.38	+$8.7K → MLLCF
3	$30,314	$7,507.11	$14,046	$367.84	+$16.3K → MLLCF
4	$42,415	$9,978.09	$15,660	$377.73	+$26.8K → MLLCF
5	$58,431	$13,047.54	$17,425	$387.07	+$41.0K → MLLCF
6	$79,320	$16,798.63	$19,354	$395.86	+$60.0K → MLLCF
7	$106,185	$21,312.20	$21,461	$404.13	+$84.7K → MLLCF
8	$140,281	$26,663.87	$23,762	$411.89	+$116.5K → MLLCF
9	$183,022	$32,921.38	$26,272	$419.15	+$156.8K → MLLCF
10	$235,976	$40,141.97	$29,010	$425.95	+$207.0K → MLLCF

MLLCF vs SCHD: Complete Analysis 2026

MLLCF — Stock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

SCHD — ETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →

📬

Get this MLLCF vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs JEPI MLLCF vs O MLLCF vs KO MLLCF vs MAIN MLLCF vs VYM MLLCF vs DGRO MLLCF vs VIG MLLCF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.